New drug combo aims to stop aggressive breast cancer from coming back
NCT ID NCT06134375
Summary
This study is testing whether adding a copper-lowering drug called tetrathiomolybdate (TM) to standard post-surgery medications can better prevent cancer from spreading or returning in people with high-risk triple-negative breast cancer. It will involve about 204 participants who have completed initial chemotherapy and surgery but still have a high risk of the cancer coming back. The research has two parts: first checking the safety of the new combination, then comparing the new regimen against standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.